Clinical Trial Update: Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MBX 2109 in hypoparathyroidism has completed, reporting safety, pharmacokinetics and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• MBX 2109 (MBX-2109)

Snippet

Sponsor: MBX Biosciences | Conditions: Hypoparathyroidism | Phase 2 | Status: COMPLETED